126 related articles for article (PubMed ID: 12881399)
1. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.
Locati LD; Quattrone P; Bossi P; Marchianò AV; Cantù G; Licitra L
Ann Oncol; 2003 Aug; 14(8):1327-8. PubMed ID: 12881399
[No Abstract] [Full Text] [Related]
2. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
3. Polymorphous low-grade adenocarcinoma of the parotid gland.
O'Rourke AK; Gourin CG; Wade ZK; Hessler RB
Ear Nose Throat J; 2006 Oct; 85(10):669-71. PubMed ID: 17124941
[TBL] [Abstract][Full Text] [Related]
4. Combined androgen blockade for salivary gland carcinoma.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
[No Abstract] [Full Text] [Related]
5. Commentary on: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
Struss WJ; Black PC
Urology; 2017 Jun; 104():5-6. PubMed ID: 28342929
[No Abstract] [Full Text] [Related]
6. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
Salvador C; Planas J; Raventós C; Ropero J; Placer J; López MA; Morote J
Actas Urol Esp; 2012 Apr; 36(4):205-9. PubMed ID: 22178349
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
[TBL] [Abstract][Full Text] [Related]
8. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
Locati LD; Perrone F; Cortelazzi B; Imbimbo M; Bossi P; Potepan P; Civelli E; Rinaldi G; Quattrone P; Licitra L; Pilotti S
Cancer Biol Ther; 2014 Jun; 15(6):678-82. PubMed ID: 24618694
[TBL] [Abstract][Full Text] [Related]
9. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
10. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
11. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Martorana G
Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
[No Abstract] [Full Text] [Related]
12. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS; Iganej S; Thompson LD
Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of acinic cell carcinoma of the parotid gland.
Chong GC; Beahrs OH; Woolner LB
Surg Gynecol Obstet; 1974 Jan; 138(1):65-8. PubMed ID: 4809004
[No Abstract] [Full Text] [Related]
14. [Prostate cancer - androgen deprivation: intermittent or continuous?].
Wedel SA
Aktuelle Urol; 2014 May; 45(3):180-1. PubMed ID: 24932555
[No Abstract] [Full Text] [Related]
15. Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.
Akyol F; Selek U; Ozyigit G; Onal C; Akdogan B; Karabulut E; Ozen H
J Natl Med Assoc; 2006 Jul; 98(7):1058-61. PubMed ID: 16895273
[TBL] [Abstract][Full Text] [Related]
16. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Taneja SS
J Urol; 2013 Dec; 190(6):2093-4. PubMed ID: 24209518
[No Abstract] [Full Text] [Related]
17. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
Palmberg C; Koivisto P; Hyytinen E; Isola J; Visakorpi T; Kallioniemi OP; Tammela T
Eur Urol; 1997; 31(2):216-9. PubMed ID: 9076469
[TBL] [Abstract][Full Text] [Related]
18. Words of wisdom. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Sciarra A
Eur Urol; 2013 Dec; 64(6):1014-5. PubMed ID: 24209449
[No Abstract] [Full Text] [Related]
19. Treatment of recurrent pleomorphic adenomas of the parotid gland.
Carew JF; Spiro RH; Singh B; Shah JP
Otolaryngol Head Neck Surg; 1999 Nov; 121(5):539-42. PubMed ID: 10547466
[TBL] [Abstract][Full Text] [Related]
20. Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature.
Abu-Ghanem Y; Mizrachi A; Popovtzer A; Abu-Ghanem N; Feinmesser R
J Surg Oncol; 2016 Nov; 114(6):714-718. PubMed ID: 27468730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]